Please provide your email address to receive an email when new articles are posted on . Sixty-six adults with binge-eating disorder were given either naltrexone/bupropion or placebo for 16 weeks. The combination of naltrexone and bupropion results in a response rate almost six times greater than with placebo in patients with moderate or severe methamphetamine use disorder, results of a new ...

Understanding the Context

FiercePharma: Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union Orexigen's Mysimba™ (naltrexone HCl / bupropion HCl prolonged release) Receives Positive CHMP Opinion Recommending Approval for Weight Management in the European Union The FDA has finally approved the use of Contrave (naltrexone hydrochloride and bupropion hydrochloride tablets), manufactured by Orexigen Therapeutics, for chronic weight management. The regimen ... FierceBiotech: Orexigen Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) Orexigen Therapeutics Presents Data on Its Proprietary Formulation of Naltrexone Sustained Release (SR) Used in Contrave(R) Nasdaq: NIDA-Funded Study Evaluating Extended-Release Injectable Naltrexone Plus Bupropion for the Treatment of Methamphetamine Use Disorder Published in New England Journal of Medicine